There is a crisis in the drug development for this hidden global epidemic of Concussion and Traumatic Brain Injury (TBI). Currently, there are no approved drugs to treat brain damage from TBI. Concussion and TBI are commonly seen in sports like NFL and in Veterans. Annual burden of TBI in U.S. is over $77 Billion and over $400Billion globally. Equally significant is the fact that it is growing each year. Symbinas Pharmaceuticals Inc. (“Symbinas”) is developing THREE drug therapeutics for Concussion and TBI. Its lead drug product, SMB-603, an intravenous formulation, has US Food and Drug Administration (FDA) approval target date of within 36 months. Key advantages include products based on strong scientific evidence, pipeline of three potential treatments, relatively fast introduction to the market using FDA 505(b)(2) and Fast-Track pathways, addressing a global market with unmet medical needs, and strong management and scientific teams. Symbinas also has several drug candidates for other serious medical illnesses including Alzheimer’s, Parkinson’s and FTD.